Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Everolimus
Drug ID BADD_D00858
Description Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Indications and Usage Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Marketing Status approved
ATC Code L01EG02; L04AA18
DrugBank ID DB01590
KEGG ID D02714
MeSH ID D000068338
PubChem ID 6442177
TTD Drug ID D0K3QS
NDC Product Code 52076-6247; 62227-019; 68254-6234; 71052-559; 49884-283; 0054-0480; 0078-0566; 0078-0620; 0078-0627; 0378-3096; 0378-3097; 67877-721; 0054-0472; 70377-012; 65129-1324; 71796-012; 0078-0422; 0093-7767; 0093-7768; 49884-119; 51991-821; 63850-0062; 63850-0064; 70377-010; 70377-011; 63850-0059; 67877-718; 0054-0470; 17404-1027; 65727-064; 0078-0567; 51991-824; 63850-0058; 0378-0007; 0378-3098; 0054-0497; 65727-063; 0078-0594; 0078-0628; 49884-158; 0378-0005; 0378-3099; 67877-720; 0054-0471; 52076-6253; 62227-013; 70225-1103; 0078-0415; 0078-0417; 0078-0626; 0054-0482; 52076-6234; 63850-0063; 67877-719; 63850-0061; 0054-0481; 0054-0604; 49884-160; 51991-822; 63850-0060; 0378-0006; 70377-013; 65727-046; 0078-0414; 0093-7766; 49884-125; 49884-127; 49884-128; 49884-159; 51991-823
UNII 9HW64Q8G6G
Synonyms Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor
Chemical Information
Molecular Formula C53H83NO14
CAS Registry Number 159351-69-6
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Viral diarrhoea07.19.02.008; 11.05.04.012---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Metastases to peritoneum07.21.03.003; 16.22.02.0080.000764%-
Angiomyolipoma15.09.01.002; 16.18.01.0020.000306%-
Glomerulonephropathy20.05.03.005---
Pneumatosis08.01.03.0440.000153%-
Ear discomfort04.03.01.0050.000520%-
Eye oedema06.08.03.0130.000229%-
Eye pruritus06.04.05.0060.001009%-
Respiratory tract congestion22.02.07.0030.000413%-
Lymphatic disorder01.09.01.0030.000153%-
Colorectal cancer metastatic07.21.01.005; 16.13.01.005---
Wound12.01.08.009; 23.03.11.043---
Nasal discomfort22.12.03.0120.000413%-
Paranasal sinus discomfort22.12.03.0180.000336%-
Foetor hepaticus07.01.06.026; 09.01.05.006---
Protein urine present13.13.02.006---
Epigastric discomfort07.01.02.004---
Musculoskeletal discomfort15.03.04.001---
Bronchitis viral11.05.04.015; 22.07.05.003---
Secretion discharge08.01.03.0190.000489%-
Wound complication12.01.08.010; 23.03.11.044--
Tumour necrosis16.32.03.009; 24.04.02.0130.000306%-
Nodule08.03.05.0020.001055%-
Cardiac discomfort02.11.04.0010.000336%-
Injection site discomfort08.02.03.018; 12.07.03.0190.000153%-
Haemorrhoidal haemorrhage07.15.03.002; 24.10.02.0010.000413%
Throat lesion22.12.03.0300.000336%-
Transaminases increased13.03.04.036---
Cerebral disorder17.02.10.0170.000229%-
The 23th Page    First    Pre   23 24 25 26 27    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene